Comparing Toxicities and Patient-Stated Preference in the SWOG S0307 Trial
June 3rd 2014Julie R. Gralow, MD, discusses an analysis of the phase III SWOG S0307 trial comparing toxicities and patient-stated preference for oral versus intravenous delivery of bisphosphonates as adjuvant therapy in primary breast cancer.